lengthi
durat
multidrug
therapi
need
cure
tuberculosi
tb
pose
signific
challeng
global
control
diseas
moreov
chronic
inflamm
associ
tb
lead
pulmonari
damag
remain
even
success
cure
thu
great
need
develop
effect
shorter
drug
regimen
improv
clinic
outcom
strengthen
tb
control
hostdirect
therapi
hdt
emerg
novel
adjunct
strategi
enhanc
efficaci
shorten
durat
tb
treatment
previous
show
administr
inhibitor
reduc
host
inflammatori
respons
mycobacterium
tuberculosi
mtb
infect
improv
antimicrobi
efficaci
isoniazid
inh
mous
rabbit
model
present
studi
evalu
pharmacokinet
explor
mechan
underli
efficaci
potent
adjunct
inh
treatment
mous
model
pulmonari
mtb
infect
genomewid
lung
transcriptom
analysi
confirm
dampen
inflamm
associ
network
gene
previous
report
consist
reduct
inflamm
signific
improv
mtb
control
patholog
observ
lung
mice
treat
plu
inh
compar
inh
alon
import
confirmatori
studi
use
help
design
upcom
human
clinic
trial
hdt
tb
treatment
lengthi
durat
multidrug
therapi
need
cure
tuberculosi
tb
pose
signific
challeng
global
control
diseas
moreov
chronic
inflamm
associ
tb
lead
pulmonari
damag
remain
even
success
cure
thu
great
need
develop
effect
shorter
drug
regimen
improv
clinic
outcom
strengthen
tb
control
hostdirect
therapi
hdt
emerg
novel
adjunct
strategi
enhanc
efficaci
shorten
durat
tb
treatment
previous
show
administr
inhibitor
reduc
host
inflammatori
respons
mycobacterium
tuberculosi
mtb
infect
improv
antimicrobi
efficaci
isoniazid
inh
mous
rabbit
model
present
studi
evalu
pharmacokinet
explor
mechan
underli
efficaci
potent
adjunct
inh
treatment
mous
model
pulmonari
mtb
infect
genomewid
lung
transcriptom
analysi
confirm
dampen
inflamm
associ
network
gene
previous
report
consist
reduct
inflamm
signific
improv
mtb
control
patholog
observ
lung
mice
treat
plu
inh
compar
inh
alon
import
confirmatori
studi
use
help
design
upcom
human
clinic
trial
hdt
tb
treatment
keyword
mycobacterium
tuberculosi
immun
modul
inhibitor
mous
model
pulmonari
tuberculosi
gene
express
hostdirect
therapi
introduct
tuberculosi
tb
caus
mycobacterium
tuberculosi
mtb
lead
killer
among
infecti
diseas
account
million
death
estim
million
new
case
standard
shortcours
chemotherapi
pulmonari
tb
involv
directli
observ
administr
four
antibiot
isoniazid
inh
rifampicin
rif
ethambutol
emb
pyrazinamid
pza
month
follow
inh
rif
therapi
month
long
durat
treatment
present
difficulti
case
manag
adher
especi
among
patient
povertystricken
commun
affect
inadequ
therapi
treatment
interrupt
greatli
elev
risk
relaps
acquisit
drug
resist
therebi
increas
potenti
transmiss
limit
therapeut
option
patient
moreov
residu
lung
damag
elev
risk
reinfect
remain
even
success
cure
tb
overcom
problem
great
need
develop
effect
shorter
drug
regimen
improv
clinic
outcom
enhanc
tb
control
howev
thu
far
effort
shorten
tb
chemotherapi
proven
unsuccess
recent
demonstr
seri
random
control
clinic
trial
show
substitut
inh
emb
one
newer
fluoroquinolon
shortcours
regimen
administ
month
led
increas
incid
relaps
compar
standard
drug
regimen
hostdirect
therapi
hdt
adjunct
convent
antibiot
regimen
emerg
novel
strategi
shorten
durat
tb
therapi
import
advantag
approach
mtb
develop
resist
drug
target
host
cell
function
evid
vitro
vivo
studi
suggest
extend
durat
tb
therapi
necessari
achiev
cure
may
explain
abil
bacilli
shift
slow
nonrepl
state
respons
standard
dose
current
avail
antibiot
nonrepl
persist
mtb
associ
divers
environment
pressur
exert
host
immun
respons
includ
hypoxia
product
reactiv
nitrogen
intermedi
capabl
drive
bacilli
toward
dormant
phenotyp
vitro
base
report
hypothes
dampen
inflammatori
respons
associ
macrophag
activ
environment
pressur
intracellular
mtb
use
adjunct
hdt
could
render
bacilli
vulner
antibioticmedi
kill
demonstr
valu
approach
show
mous
rabbit
model
adjunct
treatment
small
molecul
inhibitor
reduc
overt
inflammatori
respons
mtb
infect
significantli
improv
inhmedi
bacillari
clearanc
lung
alon
impact
growth
mtb
vitro
within
lung
anim
observ
signific
reduct
express
sever
mtb
stress
respons
gene
associ
dormanc
addit
note
chang
patholog
manifest
lung
granuloma
mice
rabbit
respons
reduct
patholog
induc
inhibit
mtbinfect
lung
indic
treatment
strategi
may
help
limit
pulmonari
damag
improv
clinic
outcom
tb
patient
present
studi
undertaken
compar
impact
murin
tb
model
second
prepar
clinic
trial
latter
drug
tb
patient
show
improv
stabil
demonstr
safeti
human
progress
phase
ii
clinic
trial
treatment
lupu
erythematosu
phase
trial
hivinfect
adult
antiretrovir
therapi
better
understand
underli
molecular
event
associ
inhibit
tb
chemotherapi
recent
studi
adjunct
inh
treatment
rabbit
model
pulmonari
tb
show
reduc
inflamm
patholog
lung
increas
antibiot
respons
infect
mtb
describ
pharmacokinet
mice
show
drug
reduc
inflammatori
respons
improv
inhmedi
bacillari
clearanc
lung
taken
togeth
result
studi
indic
promis
candid
hdt
may
shorten
durat
treatment
improv
clinic
outcom
patient
pulmonari
tb
mycobacterium
tuberculosi
grown
middlebrook
media
bd
bioscienc
md
usa
describ
ref
provid
celgen
corpor
summit
nj
usa
chemic
purchas
sigma
sigmaaldrich
mo
usa
unless
state
otherwis
anim
welfar
ethic
statement
eightweekold
femal
mice
jackson
laboratori
bar
harbor
usa
use
studi
anim
procedur
includ
aerosol
infect
oral
gavag
treatment
postinfectiontreat
monitor
perform
follow
standard
protocol
approv
institut
anim
care
use
committe
iacuc
rutger
univers
complianc
institut
government
guidelin
regul
care
use
laboratori
anim
experiment
research
n
methylsulfonyl
ethyl
cyclopropanecarboxamid
empir
formula
one
chiral
center
figur
supplementari
materi
uninfect
mice
n
per
group
treat
mgkg
oral
gavag
anoth
experi
mice
n
treat
mgkg
plu
mgkg
inh
group
mice
n
without
treatment
includ
neg
control
venou
blood
collect
h
singl
gavag
administr
without
inh
timematch
blood
sampl
also
collect
untreat
mice
anim
gavag
overnight
fast
fed
soon
gavag
plasma
collect
centrifug
blood
sampl
g
min
use
lcmsm
analysi
standard
curv
qualiti
control
prepar
mous
plasma
dilut
sorenson
citrat
buffer
mm
ph
intern
standard
prepar
mix
standard
qualiti
control
test
sampl
mous
plasma
sorenson
citrat
buffer
volvolvol
ratio
mix
centrifug
rpm
min
room
temperatur
supernat
transfer
assay
plate
lcmsm
perform
use
sciex
api
tripl
quadrupol
mass
spectromet
sciex
divis
md
inc
canada
coupl
shimadzu
hplc
system
shimadzu
scientif
instrument
md
usa
phenomenex
gemini
column
mm
mm
phenomenex
ca
usa
use
chromatographi
formic
acid
water
mobil
phase
formic
acid
acetonitril
mobil
phase
b
paramet
use
min
b
min
b
min
b
min
b
mass
spectrometr
detect
posit
ion
mode
turbo
spray
ion
sourc
temperatur
dwell
time
ms
use
analyt
quantifi
use
multipl
reaction
monitor
mrm
follow
transit
masstocharg
ratio
mz
intern
standard
respect
peak
area
ratio
analyt
intern
standard
versu
analyt
concentr
repres
quadrat
regress
plot
deriv
weight
watson
softwar
use
determin
pharmacokinet
paramet
thermo
fisher
pa
usa
peak
plasma
concentr
cmax
correspond
time
tmax
calcul
raw
data
area
plasma
concentrationtim
curv
auc
determin
linearlinearlog
trapezoid
rule
noncompartment
model
use
data
time
last
measur
time
point
auclast
statist
perform
watson
softwar
plasma
concentr
limit
quantit
bloq
treat
calcul
femal
mice
infect
mtb
use
aerosolexposur
system
ch
technolog
inc
westwood
nj
usa
describ
ref
infect
inoculum
adjust
implant
bacteri
colonyform
unit
cfu
lung
determin
actual
number
bacilli
inocul
mtbinfect
mice
n
euthan
h
postinfect
serial
dilut
whole
lung
homogen
prepar
steril
plate
middlebrook
agar
difco
laboratori
inc
detroit
mi
usa
cfu
count
follow
week
incub
mtbinfect
mice
n
euthan
day
postinfect
determin
lung
bacillari
load
cfu
patholog
time
initi
treatment
day
postinfect
mtbinfect
mice
alloc
four
group
n
per
group
treat
mgkg
inh
mgkg
plu
inh
fourth
group
mtbinfect
mice
left
untreat
control
drug
dissolv
water
administ
daili
oral
gavag
day
postinfect
mice
group
n
per
group
per
time
point
euthan
portion
lung
use
prepar
homogen
cfu
assay
store
formalin
histolog
analysi
frozen
immedi
rna
isol
serial
dilut
lung
homogen
time
point
plate
agar
supplement
inh
test
emerg
inhresist
mtb
cfu
detect
formalinfix
lung
tissu
mtbinfect
mice
paraffinembed
cut
section
stain
hematoxylin
eosin
h
e
acid
fast
stain
ziehlneelsen
zn
method
visual
host
cell
mtb
respect
idexxradil
laboratori
inc
mo
usa
describ
ref
stain
section
photograph
nikon
microphotfx
photomicrograph
system
analyz
nisel
softwar
nikon
instrument
inc
ny
usa
lung
granuloma
size
morphometr
measur
use
pathscan
enabl
iv
scanner
meyer
instrument
houston
tx
usa
sigmascan
pro
softwar
systat
softwar
inc
ca
usa
histopatholog
analysi
morphometri
perform
experienc
pathologist
blind
sampl
ident
total
rna
isol
lung
uninfect
mtbinfect
mice
without
treatment
n
per
group
day
treatment
use
trizol
reagent
invitrogen
ca
usa
describ
ref
one
microgram
total
lung
rna
mous
individu
process
cdna
synthesi
use
superscript
ii
system
agil
technolog
ca
usa
microarray
experi
perform
use
mous
genom
st
microarray
kit
affymetrix
santa
clara
ca
usa
follow
standard
protocol
data
extract
analysi
rmanorm
array
data
individu
mice
group
n
per
group
compar
follow
mtbinfect
versu
uninfect
ii
mtbinfect
versu
untreat
use
anova
partek
genom
suit
partek
inc
st
loui
mo
usa
significantli
differenti
express
gene
sdeg
identifi
use
fals
discoveri
rate
fdr
list
sdeg
analyz
use
qiagen
pathway
analysi
ca
usa
determin
significantli
enrich
p
gene
network
canon
pathway
describ
ref
microarray
data
submit
geo
access
number
total
lung
rna
ng
reversetranscrib
use
sprint
rt
kit
clontech
ca
usa
ng
cdna
use
quantit
realtim
pcr
qpcr
brilliant
ii
sybr
master
mix
agil
technolog
ca
usa
genespecif
primer
stratagen
instrument
agil
technolog
ca
usa
rox
includ
reaction
intern
control
qpcr
assay
perform
use
four
mous
sampl
duplic
per
group
data
analyz
use
mxpro
softwar
agil
technolog
ca
usa
transcript
level
gapdh
use
refer
test
gene
fold
chang
gene
express
calcul
use
formula
differ
threshold
cycl
ct
target
gene
gapdh
ratio
untreat
sampl
primer
design
base
nucleotid
sequenc
obtain
primerbank
student
ttest
graphpad
prism
graphpad
softwar
ca
usa
use
analyz
groupwis
comparison
cfu
qpcr
morphometr
data
p
consid
statist
signific
anova
partek
genom
suit
version
use
microarray
gene
express
analysi
righttail
fisher
exact
test
ingenu
pathway
analysi
use
determin
signific
pathwaynetwork
analysi
describ
ref
singl
oral
administr
three
dose
level
mgkg
demonstr
rapid
absorpt
drug
peak
plasma
concentr
reach
h
tmax
figur
supplementari
materi
test
impact
treatment
express
pattern
qpcr
perform
use
total
rna
lung
uninfect
mtbinfect
http
pgamghharvardeduprimerbank
untreat
mice
day
initi
treatment
ie
day
postinfect
figur
compar
uninfect
control
mtb
infect
induc
express
five
gene
test
lung
among
treatment
significantli
reduc
express
level
p
isoform
p
signific
chang
express
variant
note
figur
taken
togeth
result
suggest
potenti
target
although
observ
need
confirm
protein
level
figur
pca
map
also
show
median
express
level
data
within
individu
group
segreg
close
far
group
observ
show
high
level
reproduc
variabl
state
infect
treatment
within
data
obtain
differ
group
fdr
appli
array
data
found
sdeg
lung
mtbinfect
mice
rel
uninfect
control
mtbinfect
mice
sdeg
observ
rel
infect
untreat
anim
sdeg
share
treat
untreat
mtbinfect
group
figur
among
total
gene
express
sdeg
upregul
downregul
untreat
sdeg
upregul
downregul
group
affect
taken
togeth
microarray
data
suggest
mtb
infect
significantli
affect
express
thousand
host
gene
lung
express
subset
significantli
affect
figur
supplementari
materi
express
pattern
gene
consist
microarray
qpcr
determin
biolog
function
affect
differenti
host
gene
express
mtbinfect
untreat
mous
lung
analyz
respect
set
sdeg
use
ipa
tabl
gene
ontolog
go
analysi
reveal
host
cell
process
associ
infecti
diseas
inflammatori
respons
among
significantli
affect
biolog
function
mtbinfect
untreat
group
consist
progress
patholog
seen
mous
lung
see
infect
anim
biolog
function
associ
infecti
diseas
gene
express
host
cell
assembl
organ
among
significantli
affect
shown
tabl
biolog
function
affect
untreat
group
higher
level
signific
compar
moder
level
signific
group
taken
togeth
go
analysi
suggest
distinct
chang
biolog
function
affect
mous
lung
mtb
infect
without
treatment
base
go
result
extend
analysi
explor
interact
lung
inflammatori
respons
interferon
ifn
signal
networkspathway
network
pathway
play
key
role
host
immuneinflammatori
respons
mtb
infect
like
affect
antiinflammatori
activ
inhibitor
express
pattern
select
sdeg
networkspathway
valid
qpcr
figur
supplementari
materi
among
sdeg
mtbinfect
untreat
mous
lung
associ
interact
network
gene
upregul
includ
gene
induc
twofold
gene
downregul
figur
tabl
supplementari
materi
express
inflammatori
molecul
includ
tabl
supplementari
materi
upregul
mtbinfect
untreat
anim
compar
sdeg
upregul
sdeg
downregul
lung
infect
anim
figur
tabl
supplementari
materi
anim
none
sdeg
alter
twofold
chang
express
thu
treatment
significantli
dampen
express
mani
sdeg
network
upregul
respons
mtb
infect
mous
lung
one
key
proinflammatori
molecul
involv
drive
host
inflammatori
respons
progress
tb
therefor
investig
express
profil
lung
inflamm
network
mtbinfect
untreat
mous
lung
figur
tabl
supplementari
materi
avoid
repetit
sdeg
analyz
interact
network
exclud
list
gene
includ
lung
inflamm
network
subset
sdeg
infect
untreat
mous
lung
associ
inflammatori
respons
gene
upregul
includ
gene
downregul
comparison
nine
gene
upregul
four
downregul
infect
anim
figur
tabl
supplementari
materi
thu
consist
express
pattern
network
mani
sdeg
inflammatori
respons
upregul
mtb
infect
result
suggest
dampen
express
key
inflammatori
respons
molecul
trigger
mtb
infect
treat
mous
lung
recent
implic
crucial
cytokin
host
immuneinflammatori
respons
mtb
infect
probe
sdeg
mtbinfect
untreat
mous
lung
examin
differenti
express
gene
associ
total
sdeg
gene
found
associ
interact
network
mtb
infect
result
upregul
gene
includ
induc
twofold
downregul
gene
figur
b
infect
untreat
anim
downregul
signific
chang
note
express
contrast
four
gene
significantli
differenti
express
lung
infect
mice
affect
less
twofold
figur
summari
gene
interact
network
significantli
affect
mtb
infect
express
gene
dampen
suggest
downregul
network
infect
treat
mous
lung
interferon
signal
hallmark
onset
adapt
immun
respons
mtb
infect
mous
lung
expect
mani
gene
pathway
includ
upregul
mous
lung
mtb
infect
figur
b
howev
infect
anim
except
downregul
express
gene
pathway
remain
level
similar
uninfect
control
figur
tabl
supplementari
materi
determin
impact
treatment
mtbinfect
mice
inh
enumer
lung
bacillari
load
treatment
group
durat
infect
figur
figur
b
moreov
lung
homogen
infect
mice
treat
plu
inh
yield
detect
cfu
plate
media
contain
inh
indic
inhibit
associ
emerg
resist
organ
morphometr
analysi
carri
compar
extent
patholog
lung
mtbinfect
mice
differ
treatment
group
figur
mtbinfect
untreat
mice
size
area
granuloma
day
postinfect
reach
mm
time
signific
differ
lesion
area
alreadi
note
untreat
mice
treat
inh
alon
p
inh
plu
p
day
postinfect
signific
reduct
granuloma
size
note
lung
mice
treat
inh
without
adjunct
compar
untreat
group
p
respect
inh
inh
plu
infect
mice
treat
inh
plu
smaller
lesion
compar
treat
inh
alon
although
differ
statist
signific
figur
histolog
examin
lung
also
reveal
differ
patholog
treatment
group
day
postinfect
day
treatment
lung
untreat
mice
show
diffus
granuloma
mm
diamet
compris
aggreg
evenli
dispers
macrophag
lymphocyt
polymorphonuclear
cell
figur
b
supplementari
materi
time
treatment
alon
signific
impact
size
structur
lesion
confirm
immunesuppress
figur
figur
h
supplementari
materi
lesion
somewhat
smaller
untreat
group
much
smaller
area
aggreg
lymphoid
cell
day
postinfect
rel
extent
diseas
among
mtbinfect
untreat
group
similar
observ
day
although
granuloma
show
structur
cellular
organ
figur
lung
untreat
mice
granuloma
condens
somewhat
earlier
time
point
begin
coalesc
figur
b
lesion
contain
small
aggreg
macrophag
scatter
lymphocyt
surround
region
concentr
lymphoid
cell
treatment
infect
mice
alon
result
signific
differ
immun
cell
composit
lung
lesion
seen
untreat
anim
figur
contrast
granuloma
lung
mice
treat
inh
alon
smaller
compris
mainli
lymphocyt
surround
small
patch
macrophag
center
figur
f
treatment
plu
inh
result
fewer
condens
lung
lesion
compar
group
lesion
compos
dens
pack
lymphocyt
interspers
macrophag
figur
h
hostdirect
therapi
show
promis
adjunct
convent
antibiot
treatment
tb
shorten
durat
chemotherapi
improv
outcom
studi
describ
extend
previou
work
demonstr
select
immun
modul
small
molecul
adjunct
antitb
drug
inh
reduc
patholog
enhanc
antimicrobi
activ
mous
model
pulmonari
tb
studi
compar
impact
tb
treatment
previou
find
result
confirm
expand
previou
observ
provid
inform
lungspecif
isoform
target
previou
report
indic
small
molecul
drug
capac
improv
tb
chemotherapi
rolipram
cilomilast
treatment
mtbinfect
mice
show
impact
antibioticmedi
bacillari
clearanc
mous
pulmonari
tb
model
cotreat
mice
roflumilast
plu
inh
result
significantli
reduc
cfu
lung
compar
inh
alon
similar
find
variat
action
molecul
may
reflect
divers
enzym
specif
inhibitor
famili
enzym
known
subtyp
least
isotyp
differenti
express
variou
tissu
cell
type
differenti
target
specif
inhibitor
exampl
advers
gastrointestin
side
effect
limit
pharmacolog
use
rolipram
associ
specif
splicevari
isoform
roflumilast
appear
exert
antiinflammatori
effect
mainli
present
studi
treatment
alon
led
reduc
transcript
level
lung
suggest
isoform
may
specif
target
howev
analysi
distinguish
splicevari
effect
target
remain
confirm
protein
level
pharmacokinet
experi
reveal
rapid
greater
absorpt
mice
observ
rabbit
dose
mgkg
tmax
cmax
ngml
h
versu
ngml
h
respect
find
may
reflect
differ
rabbit
mice
gastrointestin
absorpt
metabol
tissu
distribut
andor
excret
coadministr
inh
mice
result
delay
tmax
h
moder
increas
plasma
cmax
auclast
observ
like
explain
welldocu
inhibitori
effect
inh
drug
metabol
mainli
inhibit
sever
cytochrom
p
isoform
liver
contrast
previou
studi
rabbit
show
effect
inh
pharmacokinet
moreov
caus
signific
chang
plasma
level
inh
cotreat
rabbit
observ
may
relev
potenti
emerg
resist
bacilli
patient
treat
antitb
drug
adjunct
hdt
note
inhresist
bacilli
recov
cotreat
rabbit
mice
investig
despit
differ
pharmacokinet
two
anim
model
effect
host
gene
express
inhmedi
mtb
clearanc
similar
support
likelihood
similar
respons
human
taken
togeth
result
studi
rabbit
mous
model
provid
rational
phase
clinic
trial
establish
appropri
dose
determin
potenti
drugdrug
interact
antimicrobi
human
go
analysi
reveal
host
cell
process
associ
infecti
diseas
inflammatori
respons
cellular
function
among
significantli
affect
biolog
function
untreat
mtbinfect
mice
observ
similar
transcriptom
profil
lung
mtbinfect
rabbit
addit
signific
chang
gene
involv
lipid
metabol
small
molecul
transport
addit
biolog
function
may
reflect
differ
physiolog
respons
mice
rabbit
mtb
infect
particularli
regard
format
differenti
granuloma
seen
rabbit
mice
mtbinfect
mice
develop
lesion
within
lung
compos
immun
cell
aggreg
minim
structur
hypoxia
enlarg
coalesc
time
contrast
rabbit
show
progress
granulomat
respons
mtb
infect
highli
structur
hypox
lesion
surround
fibrot
capsul
lesion
eventu
liquefi
form
open
caviti
similar
respons
seen
human
pulmonari
tb
despit
differ
model
show
reduc
sign
patholog
respons
adjunct
treatment
demonstr
mice
reduc
size
lung
lesion
plu
inhtreat
anim
addit
sever
gene
fibrosi
network
upregul
infect
downregul
basal
uninfect
level
respons
treatment
alon
thu
despit
lack
visibl
fibrosi
lung
mtbinfect
mice
anim
display
gene
express
profil
respons
inhibit
consist
patholog
chang
seen
mtbinfect
rabbit
receiv
treatment
although
rabbit
model
pulmonari
tb
effect
mimic
patholog
human
diseas
rabbit
genom
complet
coverag
roughli
gene
annot
basi
predict
limit
function
valid
broad
institut
reason
mous
model
provid
use
valid
transcriptom
studi
particularli
regard
earli
immun
respons
mtb
infect
well
studi
anim
genomewid
lung
transcriptom
analysi
reveal
dampen
inflammatori
responseassoci
network
gene
mice
specif
sever
gene
lung
inflamm
ifn
signal
pathwaysnetwork
upregul
mous
lung
mtb
infect
express
gene
significantli
reduc
treatment
treatment
mice
plu
inh
led
signific
improv
antibioticmedi
bacillari
clearanc
lung
compar
inh
alon
similar
previou
result
mtbinfect
mice
significantli
affect
kinet
bacillari
clearanc
earli
time
point
wherea
later
time
point
inh
alon
show
plateau
mtb
kill
cotreat
anim
continu
show
declin
cfu
reach
undetect
level
anim
day
postinfect
alter
biphas
kill
curv
seen
inh
alon
consist
hypothesi
modul
host
innat
immun
respons
lead
reduct
popul
bacilli
shift
physiolog
state
refractori
antibiot
kill
associ
host
environment
pressur
antibiot
toler
mtb
demonstr
recent
studi
liu
et
al
activ
mtbinfect
macrophag
vitro
render
bacilli
toler
four
firstlin
tb
drug
abl
kill
mtb
rest
macrophag
transcript
analysi
intracellular
bacilli
reveal
common
set
gene
differenti
express
upon
exposur
four
antibiot
moreov
perturb
bacillari
transcriptom
caus
antitb
drug
strikingli
similar
profil
differenti
express
mtb
gene
observ
insid
activ
compar
rest
macrophag
thu
observ
liu
et
al
studi
suggest
environment
pressur
mtb
within
activ
macrophag
induc
stress
respons
render
organ
toler
antitb
drug
safeti
small
molecul
antiinflammatori
agent
import
consider
select
drug
use
human
mice
rabbit
treat
alon
retain
abil
control
mtb
growth
infect
progress
indic
adapt
immun
advers
affect
contrast
uncontrol
bacillari
replic
lung
characterist
gener
immun
suppress
induc
mice
treatment
antitnf
antibodi
rabbit
treat
solubl
tnf
receptor
etanercept
thu
far
evalu
context
treatment
mice
singl
antitb
drug
inh
steep
kill
curv
observ
infect
mice
initi
expos
antibiot
may
difficult
see
addit
effect
second
antibiot
contrast
kill
curv
rabbit
organ
within
fulli
differenti
granuloma
much
slower
provid
opportun
evalu
impact
multidrug
regimen
consequ
evalu
efficaci
provid
adjunct
combin
two
firstlin
antitb
drug
inh
plu
rif
rabbit
model
pulmonari
mtb
infect
preliminari
result
indic
week
treatment
start
week
postinfect
combin
rif
plu
inh
show
enhanc
bacillari
kill
compar
inh
alon
cotreat
rabbit
togeth
inh
rif
show
reduc
cfu
lung
compar
inh
rif
alon
studi
current
progress
result
report
futur
public
conclus
result
present
publish
studi
conduct
mous
rabbit
model
pulmonari
tb
use
two
altern
inhibitor
provid
proofofconcept
adjunct
significantli
improv
antibioticmedi
bacteri
kill
reduc
lung
patholog
promis
candid
drug
hdt
improv
treatment
human
pulmonari
tb
author
contribut
ss
msk
jz
gk
design
studi
ss
msk
perform
experi
ss
msk
lt
vk
jz
df
gk
analyz
interpret
data
vk
jz
suppli
addit
reagent
studi
ss
msk
lt
df
gk
wrote
manuscript
author
read
review
edit
manuscript
agre
submiss
journal
author
thank
dr
veroniqu
dartoi
phri
pkpd
analysi
dr
erika
shor
critic
review
manuscript
studi
fund
nihniaid
grant
gk
ss
new
jersey
health
foundat
award
ss
fund
agenc
role
studi
design
data
collect
analysi
interpret
write
manuscript
supplementari
materi
articl
found
onlin
http
